Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: eico20 who wrote (2009)	7/29/2016 12:07:47 PM
From: mokelumne river	Respond to of 2026

Good and accurate list, Eman. As you point out, it looks like our best partners have not been Big Pharma. The strategy of Damaj from the beginning was to get Big Pharma on board for their credibility, experience and deep pockets to move the product and also, I think, Damaj's fear of being quickly taken over by a single Big Pharma. I have always felt that Damaj's strategy was misguided and created competition that pitted one BP against another, none of them wanting to commit resources that could benefit a competitor. The other thing, of course, was the inability to advertise in the EU. PDE5s took off in the US precisely because of Pfizer being able to advertise Viagra for what all know is a HUGE indication. I agree that IF the FDA approves, a buyout is the most logical option as Apricus is not in any way capitalized to market in the US. The odds should be in our favor for FDA approval for a whole host of reasons including approval in the EU with no reported safety issues, plenty of positive anecdotes on efficacy and no reported requests from the FDA for additional studies to address concerns that they had in 2008. The market is giving Apricus no/nada benefit for any of those reasons because Vitaros marketing never took off starting with the Abbott fiasco in Canada and lastly with the Fis failure. The Abbott, Takeda and Sandoz issues have nothing to do with the prospects for FDA consideration. But we will see.